Ivan M. AfanasoveFtek-BIO llc managing director

ef-tek.ru

EXPRESS ONCOTEST

SKOLKOVO, 05/27/2013

EFTEK-BIO LLC

2Express Oncotest

Express test microstructure

•In Russia, only 10% of of breast cancer cases are diagnosed at early stages

•only 57% women survive at least for 5 years after cancer diagnosis

•27 million women (>40 years) require annual breast screening

•It is impossible to screen such a large number of patients instrumentally and in laboratory

•Biopolymeric nanofibers

•Immobilized antibodies

•Contact of biological material with

the substrate

•Simple visualisation of the

antibody-antigene interaction

EXPRESS ONCOTESTHOME-USE TESTFOR EARLY STAGE CANCER

DIAGNOSTICS NEEDED

Problem & Solution

Market Team Action Plan

3

•The market is growing, amounting globally $ 6,4 BLN in 2020•% of elder people is steadily increasing and will reach 37% by 2050 in Russia

2013 2014 2015 2016 2017 2018 2019 2020

4.24 4.52

4.81 5.11

5.42 5.74

6.07 6.41

Global Market Volume, $ bln

Express Oncotest

Market

Team Action Plan

Problem & Solution

4

•All existing diagnostics is either instrumental (as mammography) or laboratory (requires blood analysis)•No express personal tests available

• Prompt diagnosis without laboratory equipment• Supplies as a part of National programmes for

women’s health

b2bHealth

Facilities

• Oncotest – good alternative for a mammologist consultation

• Supply to national distribution companies

b2cWomen

>40 years

Market

Team Action Plan

Problem & Solution

Breast Cancer Diagnostics

ClinicalEarly (initial)

Instrumental

LaboratoryAt home

Express Oncotest

5

Technology Business

•PhD, 17 papers, 16 patents• CEO, Eftek llc• winner of the contests for the scholarships of the President of Russia and the Academic Council of Lomonosov Moscow State University

• PhD, 192 papers• 34 years of experience in

R&D of novel functional materials• Professor at N.Semenov

Institute of chemical Physics

• PhD, 172 papers, 12 patents• 6 years experience in

electrospinning• 20 years experience in

R&D of biopolymers and biologically active molecules

• PhD, 70 papers, 9 patents•Associate Professor in

the First MGMU•Assistant rector of

RGMU after Pirogov for Science and Innovation

Medicine

Problem & Solution

MarketTeam

Action Plan

Ivan M. Afanasov, Project leader

Alexey L. IordanskiiAnalysis of structure and

properties of substrate with immobilized antibodies

Tatyana N. YudanovaSubstrate development,

immobilization of bioactive molecules

Vladislav Y. ZhemchugovBiomedical tests

Express Oncotest

6

Problem & Solution

Market Team

Action Plan

• The team• R&D and Marketing Plan• Research & Production

Facilities

• Proof-of-concept• Prototype

• R&D: qualitative analysis,

increase of sensitivity, specificity and stability

• Product registration• Ru & PCT application• Marketing

• Marketing• Pilot batch

production

COMPLETED

$ 170 000 II.2013-II.2014

$ 740 000 II.2014-II.2015

$ 440 000Sales start in III.2015

Express Oncotest

7Express Oncotest

R&D plan

Investment planCompetitor’s analysis

Project history

Business strategy

Thank you!

Questions?

Ivan M. AfanasovEFTEK-BIO LLC managing director

ivan.afanasov@gmail.comef-tek.ru

8Express Oncotest

Substrate development*

• Contains >50% nanoribbons

Immobilization of antibodies in/onto

a nanofibrous substrate

Experimental proof of the

Oncotest mechanism

Prototype

R&D Plan SEED Stage

9Express Oncotest

Action plan Completed Seed stage 1st stage

Timeline IV, 2012 I, 2013 II, 2013 III, 2013 IV, 2013 I, 2014 II,

2014III,

2014IV,

2014 I, 2015 II, 2015

R&D                      1. Development of electrospinning technology of chitosan nonorfibers containing >10% nanoribbons ˅ ˅                  

2. Development of electrospinning technology of chitosan nonorfibers containing >50% nanoribbons     ˅ ˅ ˅            

3. Development of a technology of Immobilization of antibodies in/onto a nanofibrous substrate ˅ ˅

4. Comparatative characteristics of detection of tumor markers in spittle& blood (spped, sensitivity, specificity) - literature review and development

      ˅  ˅            

5. Experimental proof of the Oncotest mechanism           ˅   ˅ ˅       a) Visualsation adaptation ˅

b) Qualitative detection of tumor markers ˅ ˅ ˅c) Preclinical tests on biological models             ˅ ˅       6.Prototype launch and technical deocumentation project development ˅

Marketing                      1. Market analysis         ˅            2. Communications with potential customers               ˅      IP                      1. Patent search           ˅          2. Рknow how registration             ˅        3. RU application              ˅      4. PCT application                  ˅  Finance                      1. Skolkovo grant       ˅              2. Venture finance/1st stage grant              ˅    

10Express Oncotest

Competitor’s analysis Breast Cancer Diagnostics

ClinicalEarly (initial)

Instrumental LaboratoryAt home

Product Stage Sensitivity SampleEase of use

Price, rub.

BrEp-test / ИХБФМ СО РАН

under development

90% Blood No 800

CanAg / Fujirebio, Sweden

on market < 1 U/mL Blood No12 000 – 24 per set (1 200 – 2 000 per 1 analysis)

PF-Biochip (РМЖ) / «Biochip-imb» llc

on market20 ng DNA in a ssample

Blood/ spittle

No ̴�of a PCR analysis

ONCOTEST / eFtek-Bio llc

under development

to be determined

Blood/ spittle/urine

YES < 800

• > 250 mln screenings annually

• Market volume $ 6,4 BLN

palpation, onco-epidemological test

ONCOTEST

radiothermometry, electrical impedance tomography, mammography,ultrasound

tumor markersRNA and DNA diagnostics

11Express Oncotest

Business Strategy

2013 - Consultations with doctors

2014-15 - Exhibitions and conferences

2015-16 – Product launch under the brand of a major

pharmacy chain + Regional dealer agreements to supply to

health facilities

2016 – Supply to national distribution companies for

pharmacy chains• Prompt diagnosis without laboratory equipment• Supplies as a part of National programmes for

women’s health

b2bHealth

Facilities

• Oncotest – good alternative for a mammologist consultation

• Supply to national distribution companies

b2cWomen

>40 years